Laura A Williams has sold ARDX and made no open-market buys since Jun 2023

Laura A. Williams, M.D., MPH, is the Chief Patient Officer at Ardelyx, Inc. (Nasdaq: ARDX), where she is responsible for championing patient-centricity and amplifying the patient voice across the organization and with external stakeholders.( She has served in this role since 2025 and previously held positions at Ardelyx as Chief Medical Officer (appointed in 2021) and Senior Vice President, Global Therapeutic Strategies and Patient Advocacy after joining the company in November 2020.( With nearly 30 years of pharmaceutical drug development experience spanning all clinical phases and multiple therapeutic areas in both large pharma and biotech, Dr. Williams has led or made major contributions to eight drug approvals.(

Before Ardelyx, Dr. Williams served as Senior Vice President and Head of Clinical Development and Biostatistics at AMAG Pharmaceuticals, overseeing four investigational-stage assets and two marketed products, and earlier as Vice President of Clinical Development at Myovant Sciences, where she was responsible for an investigational infertility compound and co-led women’s health business development activities.( She spent 18 years at Abbott/AbbVie in roles of increasing responsibility, leading multiple global clinical development programs and managing the general medicine therapeutic area.( A physician–scientist, healthcare policy advisor, patient advocate, and portfolio strategist, she holds a Bachelor of Science degree from Mississippi State University, a Doctor of Medicine from the University of Iowa, and a Master of Public Health in Epidemiology from the University of Washington, where she also completed a clinical fellowship in infectious diseases; she completed her Internal Medicine residency at the University of Michigan, serving as Chief Resident and Junior Faculty.(

Written by Perplexity from public sources.